by specicaretk | Feb 20, 2024 | Blog
For the second consecutive year, representatives from SpeciCare attended the Association for Molecular Pathology Annual Meeting and Expo in Salt Lake City, Utah. The premier gathering of molecular professionals from around the world is focused on how cutting-edge...
by specicaretk | Feb 7, 2024 | Blog
In 2024, an estimated 2,001,140 new cancer cases will be diagnosed. This equates to more than 5,000 diagnoses each day. Following the harrowing news, patients and their medical team will begin discussing treatment options to determine the plan of attack. For most, the...
by specicaretk | Feb 2, 2024 | Blog
Truthfully, I just made up that title. There is really no discipline known as “cancer tissue management science” or “biospecimen management science”. At SpeCicare, our team is investigating this space because we believe that living tissue is better for most clinical...
by specicaretk | Jan 24, 2024 | Blog
This is one of the first papers on Biospecimen Management for the Community pathologist and therefore the community patient. In 2012, SpeciCare’s Chief of Pathology David Booker convened a group of academic pathologists including those from Mass General, Duke,...
by specicaretk | Jan 24, 2024 | Blog
Why should any cancer patient question the “standard of care?” The standard of care is the thoroughly vetted and accepted way of providing cancer care. Most of the time, it provides the best opportunities for cure and survival. And, if this is so, is...
by specicaretk | Jan 17, 2024 | Blog
Melanoma tissue should be collected, frozen, and saved for potential future diagnosis and therapy, if the melanoma is advanced, recurrent, or metastatic. Frozen tissues provide the best specimen to enable the search for either the mutations that drive the cancer or...
Recent Comments